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Abstract
Background: Hypertrophic cardiomyopathy (HCM) is the most common genetic car-
diovascular disease with a broad spectrum of disease severity. HCM ranges from a
benign course to a progressive disorder characterized by angina, heart failure, malig-
nant arrhythmia, syncope, or sudden cardiac death. So far, no medical treatment has
reliably shown to halt or reverse progression of HCM or to alleviate its symptoms.
While the angiotensin receptor neprilysin inhibitor sacubitril/valsartan has shown to
reduce mortality and hospitalization in heart failure with reduced ejection fraction,
data on its effect on HCM are sparse.
Hypothesis: A 4-month pharmacological (sacubitril/valsartan) or lifestyle intervention
will significantly improve exercise tolerance (ie, peak oxygen consumption) in patients
with nonobstructive HCM compared to the optimal standard therapy (control group).
Methods: SILICOFCM is a prospective, multicenter, open-label, randomized, con-
trolled, three-arm clinical trial (NCT03832660) that will recruit 240 adult patients
with a confirmed diagnosis of nonobstructive HCM. Eligible patients are randomized
to sacubitril/valsartan, lifestyle intervention (physical activity and dietary supplemen-
tation with inorganic nitrate), or optimal standard therapy alone (control group). The
primary endpoint is the change in functional capacity (ie, peak oxygen consumption).
Secondary endpoints include: (a) Change in cardiac structure and function as
assessed by transthoracic echocardiography and cardiac magnetic resonance (MRI
imaging), (b) change in biomarkers (ie, CK, CKMB, and NT-proBNP), (c) physical activ-
ity, and (d) quality of life.
Results: Until December 2019, a total of 41 patients were recruited into the ongoing
SILICOFCM study and were allocated to the study groups and the control group.
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There was no significant difference in key baseline characteristics between the three
groups.
Conclusion: The SILICOFCM study will provide novel evidence about the effect of
sacubitril/valsartan or lifestyle intervention on functional capacity, clinical phenotype,
injury and stretch activation markers, physical activity, and quality of life in patients
with nonobstructive HCM.
K E YWORD S
familial cardiomyopathy, HCM, hereditary cardiac disease, left ventricular hypertrophy
1 | INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is the most common inherited
cardiovascular disease that affects approximately one in 500 of the
general population.1,2 Despite of advanced cardiac imaging, HCM is
still under-recognized in clinical practice and its initial diagnosis is
often delayed.2 Approximately one third of patients with HCM have
the nonobstructive form of the disease that was shown to be associ-
ated with a frequently underestimated adverse outcome.1,3
The clinical diagnosis of HCM is based on left-ventricular hyper-
trophy without cavity dilatation that cannot be explained by another
cardiac, systemic, metabolic, or syndromic disease.2,4-6 The course of
HCM is highly variable, ranging from an asymptomatic, benign condi-
tion with a normal life expectancy to an advanced disease character-
ized by angina, dyspnea, heart failure, atrial fibrillation, malignant
arrhythmia, syncope, or sudden cardiac death.2 Disease progression in
nonobstructive HCM is associated with increasing myocardial fibrosis,
microvascular ischemia, and abnormal cardiac function.3
The predominant cause are mutations of genes that encode pro-
tein components of the cardiac sarcomere and are transmitted in an
autosomal-dominant pattern.1 The mechanisms that lead from a sar-
comere gene mutation to the phenotypic expression of HCM are
poorly understood, which impedes the search for a treatment that can
disrupt this pathophysiological process.7
So far, no medical treatment has reliably shown to prevent, halt, or
reverse disease progression and targeted pharmacologic options are
scarce.8 Clinical trials demonstrated limited or no effect of angiotensin
receptor blockers or late sodium current inhibitor on disease progres-
sion, cardiac structure and function, exercise tolerance, and quality of
life in patients with HCM.9 Accordingly, treatment recommendations
are focused on the alleviation of symptoms, prevention of thromboem-
bolic events, and the prophylactic implantation of cardioverter-
defibrillators in patients at high-risk of sudden cardiac death.4,6
The angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/
valsartan is a novel treatment shown to reduce hospitalizations and
mortality in heart failure with reduced ejection fraction,10 while there
was no significant benefit of sacubitril/valsartan on the rate of total
hospitalizations for heart failure and cardiovascular death among
patients with heart failure with preserved ejection fraction in the
recently published PARAGON-HF trial.11
However, sacubitril/valsartan was shown to be more effective for
the management of hypertensive patients, compared with an angio-
tensin receptor blocker.12 Moreover, new preliminary data suggest
that sacubitril/valsartan improves exercise tolerance and left ventricu-
lar wall motion, while reducing markers of left ventricular wall
stress.13 As sacubitril/valsartan has not yet been evaluated in HCM,
this is the first clinical trial to investigate its effects on cardiovascular
performance in patients with HCM.
Lifestyle intervention is safe and can improve symptoms and signs
in patients with heart failure. Physical activity intervention is associ-
ated with a significant increase in exercise tolerance, but appears to
have limited effect on measures of cardiac morphology or function in
patients with HCM.14 Dietary supplementation with inorganic nitrate
(ie, concentrated nitrate-rich beetroot juice) improves exercise capac-
ity, vasodilatation and cardiac output reserves while reduces arterial
wave reflections, which are linked to a left ventricular diastolic dys-
function and remodeling.15-17 Combined physical activity and dietary
nitrate intervention has not previously been evaluated in HCM.
2 | METHODS
2.1 | Study design
SILICOFCM is a prospective, multicenter, open-label, randomized,
three-arm, controlled phase II clinical trial that is designed to evaluate
potential benefits of a 4-month pharmacological intervention
(sacubitril/valsartan) vs lifestyle intervention in patients with non-
obstructive HCM. The primary hypothesis and secondary hypotheses
are presented in detail in Table 1.
There are five participating institutions: Newcastle University
Medical School and Newcastle upon Tyne Hospitals NHS Foundation
Trust, (UK, coordinator), University Medical Centre Regensburg (DE),
Institute for Cardiovascular Diseases Vojvodina (RS), University of
Belgrade Clinical Centre (RS), and Careggi University Hospital Flor-
ence (IT). The Steering Committee of SILICOFCM is composed of the
five principal investigators at each participating institution (please see
also Table S3). The Steering Committee is responsible for protocol
development, protocol and regulatory compliance, safety of partici-
pants at each site, analysis and review of the data, and preparation of
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written reports for publication. Special emphasis is put on close a col-
laboration between the five participating institutions, which is ensured
by monthly teleconferences and biannual personal meetings.
The study is approved by each participating institution Research
Ethics Committee / Institutional Review Board and will be conducted
within the principles of Good Clinical Practice and in accordance with
the Declaration of Helsinki. The study is registered with ClinicalTrials.
gov (ClinicalTrials.gov-identifier: NCT03832660) and received funding
from the European Union's Horizon 2020 Research and Innovation
Programme. Obtained data will be shared with the project partners
for joint analysis.
Recruitment was started in May 2019 and enrolment is expected
to be completed in May 2021. As duration of follow-up for each
patient will be 7 months, data analysis will be finished by November
2021 and a final report will be available at the beginning of 2022.
2.2 | Subjects
Stable outpatients with a history of nonobstructive HCM or border-
line left ventricular hypertrophy are eligible if they have a left ventric-
ular wall thickness of ≥15 mm or ≥13 mm in a first degree relative of
someone with HCM and meet the inclusion and exclusion criteria
listed in Table 2. Patients are screened for eligibility and informed
consent is obtained from all eligible patients who are willing to partici-
pate in the study.
2.3 | Protocol
2.3.1 | Screening
After providing signed informed consent, participants undergo a screen-
ing visit to document age, weight/height, vital parameters, current symp-
toms, medical and family history, as well as prior, and concomitant
medication. A physical examination, a 12-lead-electrocardiogram and a
transthoracic echocardiography are performed. All participants undergo
progressive cardiopulmonary exercise testing (CPET) using a cycle
ergometer to evaluate their exercise tolerance, that is, peak oxygen con-
sumption, at baseline. A venous blood sample is drawn to examine a
comprehensive panel of serum and whole blood markers (eg, electro-
lytes, blood count, markers of renal function, muscle and liver enzymes,
NT-proBNP, lipid profile, HbA1c, TSH, and markers of inflammation).
Habitual physical activity (daily number of steps) is evaluated using
pedometers. Quality of life is assessed by the Minnesota Living with
Heart Failure Questionnaire, the Hospital Anxiety and Depression Scale
as well as the SF12-v2. At the time of enrolment, all participants must be
on optimal standard therapy for HCM, conforming to contemporary
guidelines such as the European Society of Cardiology guidelines. All car-
diac medications must remain unchanged for at least 2 weeks before
screening and randomization.
2.3.2 | Randomization
Eligible participants with signed informed consent are randomly allo-
cated to the study groups—receiving either treatment with sacubitril/
valsartan or lifestyle intervention—or the control group (optimal stan-
dard therapy) using consecutively numbered sealed envelopes. Ran-
domization will be stratified by patients giving or declining informed
consent for the optional cardiac MRI-imaging. If 10 patients are ran-
domized within the cardiac MRI-stratum, no further patients will be
added to this stratum.
2.3.3 | Pharmacological intervention
Participants who are allocated to the pharmacological study group
and have previously received an angiotensin-converting enzyme
inhibitor- or angiotensin receptor blocker-therapy will require a
36-hour washout period before initiation of sacubitril/valsartan to
reduce the risk of angioedema.18 The treatment period begins with
the initial dosing of sacubitril/valsartan, followed by up-titration every
14 days to the target dose of 97/103 mg twice daily. The three doses
of sacubitril/valsartan available throughout the study are 24/26 mg
TABLE 1 Primary and secondary hypotheses





tolerance (ie, peak oxygen
consumption) in patients with
nonobstructive hypertrophic
cardiomyopathy (HCM)
compared to the optimal
standard therapy (control
group).






MRI imaging (ie, magnitude or
distribution of cardiac
hypertrophy, degree of left
ventricular outflow
obstruction, systolic and
diastolic function, and left
ventricular wall motion)
compared to the optimal
standard therapy.
2. A 4-month pharmacological or
lifestyle intervention will
significantly improve injury
and stretch activation markers
(ie, CK, CKMB, and
NT-proBNP) compared to the
optimal standard therapy.
3. A 4-month pharmacological or
lifestyle intervention will
significantly improve quality of
life (as determined by the
SF12-v2-, Minnesota Living
with Heart Failure-, and
Hospital Anxiety and
Depression-questionnaires)
compared to the optimal
standard therapy.
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(dose level 1), 49/51 mg (dose level 2), and 97/103 mg (dose level 3),
each taken by mouth twice daily.
Doses may be adjusted based on overall safety and tolerability.
If necessary, dose adjustments or elimination of concomitant medi-
cations is made to alleviate adverse effects. If adverse effects are
not alleviated or it is not possible to adjust concomitant medica-
tions, the study treatment may be down-titrated by one dose
level—or, at the lowest dose, temporarily withdrawn—for 1 to
2 weeks. Participants may then be reassessed and the study
treatment further down-titrated every 1 to 2 weeks until being
deemed stable. Once stability is achieved, the participant is re-
challenged with up-titration to the target dose. In case of discon-
tinuation of the study medication, the participant is advised to
return to the clinic for an end-of-study visit. Participants undergo
treatment for 4 months.
After enrollment into the study, all participants are instructed to
notify the study site about any change or withdrawal of medication.
Furthermore, all medication, medical procedures and significant
TABLE 2 Inclusion and exclusion criteria
Inclusion criteria
1. Adults ≥18 years of age
2. Confirmed diagnosis of hypertrophic cardiomyopathy
3. Agreement to be a participant in the study protocol and willing/able to return for follow-up
4. Able to provide written informed consent
5. In women of childbearing age: Willingness to use a highly effective contraceptive method (failure rate per year <1%)
Exclusion criteria
1. Less than 3 months postseptal reduction therapy (surgery or catheter-based intervention)
2. Clinical cardiac decompensation in the previous 3 months, defined as New York Heart Association class IV congestive heart failure symptoms
3. Resting blood pressure >180/100 mmHg or systolic blood pressure <100 mmHg
4. Hypotensive response to exercise testing (≥20 mmHg decrease of systolic blood pressure from baseline blood pressure or an initial increase in
systolic blood pressure followed by a decrease of systolic blood pressure ≥20 mmHg)
5. Concomitant use of angiotensin converting inhibitors or angiotensin receptor blockers; patients previously receiving angiotensin-converting
enzyme inhibitor or angiotensin receptor blocker therapy will require a 36-hour washout period before initiation of Sacubitril/Valsartan
6. Resting left ventricular outflow tract gradient >50 mmHg
7. Left ventricular ejection fraction <50% by echocardiography
8. Implanted pacemaker or cardio-defibrillator in the last 3 months or scheduled
9. History of hyperkalemia (serum potassium >5.2 mmol/L)
10. Renal insufficiency with a glomerular filtration rate <30 mL/min per 1.73 m2
11. Present or planned pregnancy
12. Life expectancy less than 12 months
13. Patients with severe adipositas (adipositas permagna, body mass index >40 kg/m2)
14. History of exercise induced syncope or sustained ventricular arrhythmias
15. Inability to exercise due to orthopedic or other noncardiovascular limitations
16. Use of other investigational drugs at the time of enrolment
17. Concomitant treatment with aliskiren-containing drugs; discontinuation of treatment with aliskiren-containing drugs is required before initiation
of Sacubitril/Valsartan
18. History of angiotensin converting inhibitors- or angiotensin receptor blockers-induced angioedema or history of hereditary or idiopathic
angioedema
19. Evidence of hepatic disease as determined by any one of the following: AST or ALT values exceeding 2× ULN, severe hepatic insufficiency
(classification Child Pugh C), biliary cirrhosis, cholestasis (current or anamnesic evidence), history of hepatic encephalopathy, history of esophageal
varices, or history of portocaval shunt
20. Any surgical or medical condition that in the opinion of the investigator may place the patient at higher risk from his/her participation in the study
or is likely to prevent the patient from complying with the requirements of the study or completing the study
21. History of noncompliance to medical regimens and patients who are considered potentially unreliable
22. History or evidence of drug or alcohol abuse within the past 12 months
23. History of malignancy of any organ system (other than localized basal or squamous cell carcinoma of the skin or localized prostate cancer), treated
or untreated, within the past 2 years, regardless of whether there is evidence of local recurrence or metastases
24. Life-threatening or uncontrolled dysrhythmia, including symptomatic or sustained ventricular tachycardia and AF or atrial flutter with a resting
ventricular rate >110 beats per minute
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nondrug therapies (eg, blood transfusions and physical therapy) admin-
istered after the patient has been enrolled into the study are recorded.
2.3.4 | Lifestyle intervention
A 4-month lifestyle intervention in patients with HCM consists of two
integrated components, that is, physical activity and dietary supple-
mentation with inorganic nitrate. In brief, the physical activity compo-
nent aims to increase the patients' daily activity level by at least 2000
steps/day from baseline (eg, walking for approximately 30 minutes) at
least 5-7 days per week. To control for exercise intensity, patients will
be instructed to use the standardized Borg Rating of Perceived Exer-
tion Scale (6–20) to rate perceived exertion and to aim for levels
between 11 and 14 (fairly-light to somewhat hard; please refer to the
online supplement and Table S1 for details). The exercise prescription
will be progressed individually as conditioning takes place. No
strength training or burst activity will be prescribed, all activities will
fall well within the recommended national guidelines for recreational
exercise19 and all participants are counseled to be alert to warning
signs and symptoms that should prompt them to stop exercising and
to seek medical advice.
The second component of the lifestyle intervention is a dietary
supplementation with inorganic nitrate with a single dose of inorganic
nitrate (NO3−) given in the form of concentrated nitrate-rich beetroot
juice (NO3−, BEET IT Sport, James White Drinks Ltd., Ipswich, United
Kingdom) containing 6 mmol of NO3− in a 70 mL bottle. Instructions
will be provided for self-administration of the nutritional intervention
and patients will be asked to consume the beetroot juice each morning
with the breakfast for 4 months. The EPIC-Norfolk Food Frequency
Questionnaire (please refer to the online supplement for details) will be
administered at baseline and the Food frequency questionnaire EPIC
Tool for Analysis (FETA) software used to extract dietary (energy and
nutrient) information.20 Adherence to the lifestyle intervention will be
tracked by completion of activity logs and self-reported diaries, weekly
telephone follow-ups, as well as pedometers.
2.3.5 | Optimal standard therapy (control group)
Participants in the control group receive optimal standard therapy for
HCM as advocated in the current guideline of the European Society
of Cardiology.6 Optimal standard therapy may include an appropriate
lifestyle, adequate management of heart failure symptoms and atrial
fibrillation as well as risk stratification and preventive measures
against sudden cardiac death.
2.3.6 | Echocardiogram
A transthoracic echocardiogram is performed by qualified cardiolo-
gists who are blinded to the participants' treatment allocation. Each
study includes M-mode and 2-D images obtained from the standard
parasternal and apical windows with three cardiac cycles being
recorded. The echocardiogram—comprising color and tissue doppler—
is done at rest and in response to the Valsalva maneuver, in order to
detect a potential left ventricular outflow tract obstruction. Biplane
Simpson's method is used for measurement of left ventricular (LV)
end-diastolic and end-systolic volumes from which LVEF is derived.
Details on the echocardiogram protocol and all assessed echocardio-
gram parameters are summarized in the online supplement and in
Table S2.
2.3.7 | Cardiopulmonary exercise testing
A progressive CPET with a bicycle ergometer is performed to obtain a
comprehensive assessment of pulmonary, cardiac, and circulatory
function. At rest, during the exercise and throughout the recovery
phase, an ECG is continuously monitored, and blood pressure and
heart rate are frequently measured. At first, resting baseline values
are recorded for 3 minutes. Then, the participants start pedaling for
3 minutes without any resistance at a pedal frequency of 60-70 rpm,
followed by a continuously increasing resistance at the predetermined
ramp rate of 10 W/minute. The CPET is terminated, if complications
(ie, significant ST-segment deviation) arise, when the patient is unable
to maintain a pedal-frequency above 60 rpm or voluntary stops the
exercise due to severe symptoms, such as breathlessness or exhaus-
tion. Please refer to the online supplement for details.
2.3.8 | Electrocardiogram and ECG holter
monitoring
The ECG will be performed using a standard 12-lead-
electrocardiogram in supine position. To identify sporadic arrhythmia,
all participants are asked to wear an ECG-holter-monitor for 24 hours
and to keep a diary of activities and symptoms. The ECG-holter-
recording is then correlated with the participants' activities and
symptoms.
2.3.9 | Assessment of quality of life and habitual
physical activity
Participants are asked to complete the validated and self-administered
SF12-v221- and Minnesota Living with Heart Failure-questionnaires22
and the Hospital Anxiety and Depression Scale23 at baseline and as
part of the clinic visits after 4 and 7 months, in order to assess general
and disease specific quality of life. Permissions to use the SF12-v2-
and Minnesota Living with Heart Failure-questionnaires and the Hos-
pital Anxiety and Depression Scale were obtained from the copyright
holders. Please refer to the online supplement for details on the
assessment of general and disease-specific quality of life. Habitual
physical activity will be evaluated using pedometer for counting daily
number of steps over a 7-day period.
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2.3.10 | Optional genetic testing
Participants who have given written informed consent are offered
an optional genetic testing for mutations in genes associated with
HCM. An investigator, who is well-qualified in cardiac genetic
counseling, clarifies what genetic testing might reveal and how
family members might benefit from that knowledge. If participants
choose to be genetically tested, they will be asked to provide writ-
ten informed consent.
The genetic testing requires a blood sample and is performed at
the Institutes of Human Genetics at the University Hospital Regens-
burg. The gene panel includes polymerase chain reaction (PCR)-based
assays to detect the following 34 genes, including all common and
most rare variants with known clinical significance: ACTC1, ACTN2,
ANKRD1, CALR3, CASQ2, CAV3, CRYAB, CSRP3, DES, FHL1, FLNC,
GAA, GLA, JPH2, LAMP2, LDB3, MYBPC3, MYH6, MYH7, MYL2,
MYL3, MYLK2, MYOZ2, MYPN, NEXN, PLN, PRKAG2, TCAP,
TNNC1, TNNI3, TNNT2, TPM1, TTR, VCL. Genetic findings will be
discussed with the patients in detail and—in case of positive results—
patients will be invited for genetic counseling to identify relatives at
an increased risk for HCM.
2.3.11 | Optional cardiac MRI-imaging
Participants who have given written informed consent are offered an
optional cardiac MRI-examination. If patients choose to participate in
the cardiac MRI-examination, they will be asked to provide written
informed consent. The cardiac MRI-examination is implemented to
evaluate cardiac morphology as well as systolic and diastolic function.
Perfusion imaging is performed to assess first-pass perfusion during
bolus injection of 0.1 mmol/kg of gadolinium contrast agent. Phase
sensitive 2D inversion-recovery prepared gradient Echo imaging will
be done 15-20 minutes post injection to evaluate for delayed
enhancement of the myocardium. Please refer to the online supple-
ment for details on cardiac MRI imaging.
2.3.12 | Follow-up
The study schedule for participants is illustrated in Figure 1. Following
screening and randomization, all participants attend clinic visits after
4 and 7 months, during which the assessments performed at baseline
are replicated (Table 3). Moreover, participants in the study group are
offered two additional visits to ensure medicinal safety before up-
titrating the sacubitril/valsartan-dose after approximately 14 and
28 days. To detect the most common side effects of sacubitril/
valsartan, that is, symptomatic hypotension, hyperkalemia and renal
impairment, a physical examination is performed, current symptoms
and concomitant medication are reviewed, and a blood sample is
assessed for potassium and markers of renal function.
Between planned visits, an extra clinic visit may be required
when: (a) the patient reports an adverse event that in the investiga-
tor's opinion warrants further assessment, or (b) the patient irrevers-
ibly discontinues the study medication with sacubitril/valsartan, if
tolerability issues cannot be alleviated.
F IGURE 1 Study flow chart
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2.3.13 | Outcomes
The primary study endpoint is the change in exercise tolerance (ie,
peak oxygen consumption, peak VO2) in CPET. Secondary endpoints
include: (a) Change in clinical phenotype in transthoracic echocardi-
ography and cardiac MRI imaging (ie, magnitude or distribution of
cardiac hypertrophy, degree of left ventricular outflow obstruction,
systolic and diastolic function, and left ventricular wall motion),
(b) change in injury and stretch activation markers (ie, Creatine
kinase (CK), creatine kinase-myocardial band (CKMB), and NT-
proBNP), (c) change in habitual physical activity, and (d) change in
quality of life (as determined by the SF12-v2-, Minnesota Living with
Heart Failure-Questionnaire, and Hospital Anxiety and Depression
Scale).
TABLE 3 Study schedule
Trial period
Screening/




Valsartan/Lifestyle Intervention Follow up
Premature treatment
discontinuation
Visit number/title Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Discontinuation visit
Schedules days/week/month day 1 Day 14 Day 28 Week 16 (month 4) Week 28
(month
7)





± 2 days ± 2 days ± 2 weeks ± 2 weeks
Administrative procedures
Informed consent x













Weight/height x x x x
Vital signs (blood pressure,
pulse etc.)
x x x x x x
Physical exam x x x x x x





x x x x x x
Electrocardiogram (12-lead) x x x x
Transthoracic echocardiogram x x x x
Cardiopulmonary exercise
testing
x x x x
ECG holter monitoring x x
Blood work x x x x x x
Quality of life questionnaires x x x x
Adverse events monitoring x x x x




for imaging sub-study (if
applicable)
(x) (x)
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3 | STATISTICAL ANALYSIS
3.1 | Sample size and power calculation
The aim of the present study is to provide novel evidence about the
efficacy and safety of sacubitril/valsartan vs lifestyle intervention in
patients with nonobstructive HCM. In the absence of preliminary data
regarding expectable treatment effects, we aim to enroll a total of
240 participants randomized into one of the three study arms. The
average peak oxygen consumption in patient with HCM is suggested
to be approximately 22 mL/kg/min.14 The same study in patients with
HCM has demonstrated a 10% increase in peak oxygen consumption
with 8-12 weeks of lifestyle/exercise intervention.14 Assuming a simi-
lar effect, the present study plans to enroll 80 patients per interven-
tion to have 90% power to detect a significant difference in peak
oxygen consumption between the groups, at a two-tailed significance
level of 0.05 or less.
3.2 | Analysis population
The primary analyses will be based on the intention-to-treat (ITT)
analysis set, consisting of all patients who entered the study (ie, all
patients who received a patient identification number). However, sen-
sitivity analyses will be done on a per-protocol (PP) analysis set that is
composed of the ITT analysis set without major protocol violations.
The latter serves to assess the robustness of the results. All safety
data will be analyzed by means of the safety population of all study
patients who had at least one post-baseline safety assessment. The
statement that a patient had no adverse events also constitutes a
safety assessment.
3.3 | Data analysis
Statistical analyses will be performed using SPSS software version
24.0 or higher (IBM SPSS Statistics, Armonk, New York). Data will be
described as mean and SD for normally distributed data, as median
(25.;75. percentile) for non-normally distributed data and as numbers
and percentages of participants for categorical variables. Differences
in baseline characteristics, and outcome variables between the
treatment- and control-group will be compared using the analysis of
variance (ANOVA) for normally distributed continuous variables, the
Kruskal-Wallis test for non-normally distributed continuous variables
and the Persons chi-square test for categorical variables. A two-sided
P-value of ≤.05 will be considered statistically significant for all ana-
lyses. As all secondary endpoints are of exploratory character, no
adjustment for multiple testing will be performed.
4 | RESULTS
Until December 2019, a total of 41 patients were recruited into the
ongoing SILICOFCM study and were allocated to the study groups—
receiving either treatment with sacubitril/valsartan (n = 14) or lifestyle
intervention (n = 7)—and the control group (optimal standard therapy;
n = 20). The mean age of the study population was 59.7 ± 13.4 years
and 62% were male. Patients were diagnosed with hypertrophic non-
obstructive cardiomyopathy with a mean maximum wall thickness of
19 ± 4 mm. There was no significant difference in key baseline char-
acteristics between the three groups. Please refer to Table 4 for more
details on key baseline characteristics.
5 | DISCUSSION
Until recently, nonobstructive HCM was predominantly regarded as a
pathophysiologically benign disorder without significant symptoms,
high-risk characteristics or the necessity for major treatment options.5
However, nonobstructive HCM has been linked to increased morbid-
ity due to a high risk for malignant ventricular arrhythmia3 that may
be caused by myocardial fibrosis and microvascular ischemia.24 As
treatment options in patients with nonobstructive HCM are usually
restricted to pharmacological therapy, promising new drugs, such as





intervention Lifestyle intervention P-value
n (%) 41 (100) 20 (49) 14 (34) 7 (17)
Age, years 59.7 ± 13.4 61.6 ± 13.9 60.3 ± 10.4 52.7 ± 16.5 0.315 A
Male sex, n (%) 26 (62) 11 (55) 9 (64) 6 (86) 0.347 Chi
Body mass index, kg/m2 27.7 ± 3.9 27.9 ± 4.4 26.5 ± 3.4 29.4 ± 3.4 0.286 A
Left ventricular ejection fraction, % 64.1 ± 7.1 65.4 ± 6.6 63.9 ± 8.5 61.1 ± 5.3 0.410 A
Maximal wall thickness, mm 19 ± 4 18 ± 4 21 ± 5 17 ± 2 0.092 A
Resting LVOT gradient, mmHg 17.5 ± 15.3 17.1 ± 11.9 18.0 ± 23.5 18.0 ± 4.2 0.984 A
Note: Key baseline characteristics of the study population of patients that were enrolled into the ongoing SILICOFCM study until December 2019 (n = 41)
according to their allocation to the study groups—receiving either treatment with sacubitril/valsartan or lifestyle intervention—or the control group
(optimal standard therapy). Data are presented as mean ± SD unless otherwise stated. Chi, Chi-square test; A, ANOVA; LVOT, left ventricular outflow
tract.
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sacubitril/valsartan, are essential and need to be investigated in clini-
cal studies.
Lifestyle intervention has been shown to improve exercise toler-
ance in HCM but at the same time limited effect on cardiac structure
and function was reported.14 Recent studies have demonstrated that
dietary supplementation with inorganic nitrate improves exercise
capacity and hemodynamic function in patients with heart failure pre-
served ejection fraction.15-17 The potential physiological effect of a
combined physical activity and dietary nitrate on HCM phenotype has
not been previously investigated and is subject to evaluation in the
present SILICOFCM study.
Therefore, our randomized controlled clinical SILICOFCM trial will
provide a novel evidence about the safety and efficacy of sacubitril/
valsartan vs lifestyle intervention in patients with HCM. Secondly,
several exploratory endpoints will complement primary analyses with
regard to potential changes in clinical phenotypic characteristics,
injury and stretch activation markers, and quality of life. Thirdly, com-
prehensive genetic analyses may further elucidate the complex
genotype-phenotype relationship characteristic of HCM and its
impact on treatment response.
5.1 | Assessment of sacubitril/valsartan in patients
with nonobstructive HCM
Having once been considered as contraindicated due to concerns for
potential hemodynamic complications, CPET is nowadays a well-
established clinical tool in the comprehensive evaluation of HCM
patients.25,26 The medical benefits of CPET in HCM comprise the dif-
ferentiation of mild left ventricular hypertrophy from physiological
hypertrophy,27 a better prediction of disease progression as well as
the objective evaluation of therapeutic strategies and treatment
effects.25,26
The change in peak VO2 in CPET was chosen as primary endpoint
of this study, because peak VO2 is considered a factual parameter for
assessing exercise capacity in patients with HCM.28 Moreover, low
peak VO2 is generally acknowledged as an independent predictor for
major adverse events in HCM, while normal peak VO2 is associated
with a favorable clinical outcome.25
Besides, the SILICOFCM trial covers a wide range of second-
ary outcome parameters, for example, clinical phenotypic character-
istics, injury and stretch activation markers, quality of life, and
physical activity, that will be assessed in an exploratory manner.
Accordingly, the SILICOFCM aims to evaluate the effect of
sacubitril/valsartan vs lifestyle intervention on nonobstructive HCM
in a comprehensive way.
5.2 | Potential mechanisms of action of sacubitril/
valsartan intervention in nonobstructive HCM
The underlying pathophysiology and mechanisms of HCM lead to
increased myocardial fibrosis and hypertrophy. This may be mediated
by microvascular ischemia and an up-regulated feedback loop of the
renin-angiotensin-aldosterone system.8 By simultaneously blocking
the renin-angiotensin-aldosterone system and augmenting natriuretic
peptides through neprilysin inhibition,29 the ARNI sacubitril/valsartan
promotes vasodilatation, natriuresis and inhibition of fibrosis and
hypertrophy.30,31 Thus, sacubitril/valsartan has already emerges as an
innovative and promising therapeutic approach in heart failure with
reduced ejection fraction.10
So far, the potentially beneficial effects of sacubitril/valsartan
in HCM has not been evaluated in clinical trials. Therefore, first
mechanistic insight must be derived from experimental data and a
single case report: Sacubitril/valsartan was shown to attenuate left
ventricular remodeling and dysfunction by inhibiting cardiac fibro-
sis and hypertrophy in both in vivo- and in vitro-analyses.29 The
first positive response to treatment with sacubitril/valsartan in
HCM has been described in a case report by Rubis et al.32: a
middle-aged woman with nonobstructive end-stage HCM was
treated with sacubitril/valsartan for 3 months, which resulted in
marked improvements in symptoms and exercise tolerance as well
as an enhanced left ventricular function and decreased NT-
proBNP levels.32
5.3 | Potential mechanisms of action of lifestyle
intervention in nonobstructive HCM
While aerobic exercise training was shown to improve cardiovascular
health and overall survival in the general population,33,34 data on the
safety and benefit of recreational exercise for patients with HCM is
still scarce.35,36 However, a study by Saberi et al. showed that
moderate-intensity exercise training over a period of 16 weeks in
patients with HCM significantly improved their exercise capacity com-
pared to usual activity.14 Most importantly, exercise training in
patients with HCM was safe without any occurrences of sustained
ventricular arrhythmia, sudden cardiac arrest, appropriate defibrillator
shock or death.14
Recently, several reports demonstrated that dietary supplementa-
tion with NO3−—that is particularly abundant in beetroot juice—
increases exercise capacity in patients suffering from heart failure
with preserved ejection fraction.15-17 Ingested NO3− is converted to
nitrite (NO2−) by anaerobic bacteria in the oral cavity
37 that is subse-
quently reduced to nitric oxide (NO) by metalloproteins (eg,
deoxyhemoglobin or deoxymyoglobin).38 This conversion and delivery
of NO occurs preferentially in the setting of hypoxemia and thus, may
ultimately decrease systemic vascular resistance and increase cardiac
output during physical exercise.17
5.4 | Genetic testing
As a particular feature of the present study, all participants are offered
comprehensive genetic testing for mutations in genes associated with
HCM. Due to variable penetrance and expression,39 the phenotypic
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characteristics of HCM are multifaceted and may be influenced by
other factors beyond single pathogenic mutations.40 The complex
genotype-phenotype characteristics of HCM were potentially under-
recognized in the past, which may have resulted in an unsatisfactory
efficacy of drug management.40 Therefore, our clinical trial may con-
tribute to a better understanding of the association between sarco-
mere mutations and phenotype characteristics and disease severity as
well as its impact on treatment response.
6 | LIMITATIONS
The design of the SILICOFCM has a few limitations to be consid-
ered, in particular the short treatment period. Preliminary data
about expectable treatment effects of sacubitril/valsartan in
patients with nonobstructive HCM is missing to date. The sample
size of this trial was considered sufficient to get robust effect esti-
mates in regard to the efficacy and safety of the study treatments.
Participants undergo study treatment for 4 months, which was
deemed sufficient to observe potentially beneficial effects of the
complementary addition of sacubitril/valsartan to the optimal stan-
dard therapy of HCM. Comparable treatment durations with
sacubitril/valsartan were previously shown to significantly reduce
NT-proBNP in patients with heart failure with preserved ejection
fraction41 and to improve cardiac function in the above mentioned
case report of a patient with HCM.32
Due to the above-mentioned limitations, the results of our trial
may have to be interpreted with caution. However, they may pave
the way for future clinical trials on patients with
nonobstructive HCM.
7 | CONCLUSION
Over the past decade, we have gained a better understanding of the
clinical management of patients with HCM. There have been consid-
erable advances in treatment strategies directed at symptomatic relief
and the prevention of sudden cardiac death. Henceforth, new
approaches need to be evaluated regarding their potential to halt the
phenotypic expression and progression of HCM.
In this aspect, SILICOFCM will provide novel data on whether
the complementary addition of sacubitril/valsartan or lifestyle inter-
vention to the optimal standard therapy improves cardiovascular
performance in patients with nonobstructive HCM as well as their
clinical phenotypic characteristics, injury and stretch activation
markers, habitual physical activity, and quality of life. The
SILICOFCM study has the potential to generate rational hypothe-
ses regarding the effect of sacubitril/valsartan or lifestyle interven-
tion on functional capacity in patients with nonobstructive HCM
that then need to be confirmed in larger randomized clinical trials.
Thus, SILICOFCM will clearly contribute to optimizing the manage-
ment of patients with nonobstructive HCM and to improving their
clinical outcome.
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